top of page
  • Writer's pictureFutureMeds

FutureMeds Appoints Business Development Leader Cameron Glen to further accelerate growth

Updated: Jan 24, 2023

FutureMeds has appointed Cameron Glen as Vice President of Business Development. Cameron will be responsible for building key alliances with customers and shaping Futuremeds partnerships and services.

Cameron has joined the company to further strengthen FutureMeds’ position as a top tier independent Site Management Organisation. As a business development leader, Cameron comes with a wealth of knowledge and experience, and brings strong operational & growth insights to the challenges of clinical studies.

“Cameron brings us his great expertise of site operations combined with a great network of industry leaders. I am sure that his presence in the team will be critical for FutureMeds' European expansion. I am really looking forward to working with him on expanding our client portfolio.”

- Dr. Radoslaw Janiak, CEO of FutureMeds

Cameron has a unique blend of industry experience and knowledge that all SMOs need to continue to build relationships with, and cater to, the specialised demands of our market. He spent 23 years of his career building & forging alliances and pursuing new business for notable public and private sector players such as Menarini Pharmaceuticals, AstraZeneca, University of Dundee/NHS Tayside, Synexus, and industry-leading CROs such as Covance Inc. (Labcorp R&D) and ICON plc.

Cameron has also a strong track record as a site director. For over 3 years, he led the Synexus’ Scotland Clinic with key responsibilities including P&L, operational management, local patient engagement and delivery of industry Phase 2b to 4 clinical research.

In his new role with FutureMeds, Cameron will be responsible for leading the independent SMO’s business development activities, expanding business models and building strategic and trusted relationships across a broad network of pharmaceutical leaders, CROs and sponsors.

“Quality research remains the fundamental cornerstone of how we improve medications and health outcomes. In my role, my key priority will be to continue to build upon the existing relationships and bring new clinical trial opportunities from our Sponsor and CRO partners to FutureMeds as this will support the expansion plans of our sites over the coming years.”

“I will also support the shaping of Futuremeds partnerships and our services offerings to the marketplace. It is an exciting place to be. I feel I have returned home to what I believe is an exceptional leadership team and I look forward to building new alliances with key customers over the coming months.” commented Cameron Glen, Vice President of Business Development at FutureMeds.

FutureMeds is a fast-growing independent Site Management Organisation and currently operates 12 sites across 4 countries. It is already in the top tier of Dedicated Research Site Networks in Europe and its’ Dedicated Research Sites across the continent are currently involved in running clinical trials on behalf of its clients in pharma and CROs.

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Commenting has been turned off.
bottom of page